{"id":"W2488647697","doi":"10.1016/j.leukres.2016.07.004","title":"A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)","year":2016,"lang":"en","type":"article","venue":"Leukemia Research","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Merck","keywords":"Medicine; Regimen; Tolerability; Internal medicine; Refractory (planetary science); Gastroenterology; Phases of clinical research; Adverse effect; Surgery; Clinical trial; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008199946,0.001236225,0.001779322,0.0003102234,0.0003008856,0.0008499969,0.0006997552,0.0008598706,0.003520333],"category_scores_gemma":[0.0005502722,0.0004384266,0.0008102803,0.0003262709,0.0006819807,0.0006321438,0.0003100138,0.002649048,0.000823713],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005662506,"about_ca_system_score_gemma":0.0009938456,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008603783,"about_ca_topic_score_gemma":0.002376532,"domain_scores_codex":[0.9998235,0.00007478546,0.000007181721,0.00003099205,0.00001260067,0.00005094782],"domain_scores_gemma":[0.9996727,0.00005293577,0.00004758006,0.00002731212,0.00001298269,0.0001865186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7601201,0.02753105,0.004369064,0.0010582,0.001431153,0.0003589166,0.0003100641,0.003507035,0.05200775,0.0007579791,0.008479387,0.1400693],"study_design_scores_gemma":[0.7327569,0.2448618,0.009401518,0.00004030402,0.0005887757,0.000419043,0.00008007535,0.001601383,0.004421686,0.0003194098,0.005472985,0.00003604807],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903705,0.003641345,0.0005391258,0.0007236371,0.0002045746,0.001063413,0.0008418805,0.0001847633,0.002430858],"genre_scores_gemma":[0.9895651,0.0029919,0.001207529,0.0007444606,0.0001821905,0.001014149,0.001737243,0.00003391316,0.002523464],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003520333,"threshold_uncertainty_score":0.01177669,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05038255470315886,"score_gpt":0.3669708376196864,"score_spread":0.3165882829165275,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}